Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Hypoaldosteronism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypoaldosteronism with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Acidosis, Renal Tubular Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Acidosis, Renal Tubular in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Gordon Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Gordon Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
SeSAME Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate SeSAME Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypomagnesemia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypomagnesemia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypomagnesemia 5, Renal, With Ocular Involvement Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypomagnesemia 5, Renal, With in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Paralysis, Hyperkalemic Periodic Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Paralysis, Hyperkalemic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypokalemic Periodic Paralysis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypokalemic Periodic Paralysis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Pseudohypoaldosteronism Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Pseudohypoaldosteronism in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Mineralocorticoid Excess Syndrome, Apparent Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Mineralocorticoid Excess in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Hypertension, Renovascular Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Hypertension, Renovascular in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Aneurysm, Dissecting Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
13 August 2026
Evaluate Aneurysm, Dissecting with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..